Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Sep;36(3):205–209. doi: 10.1111/j.1365-2125.1993.tb04218.x

The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril.

N J Macdonald 1, A Sioufi 1, C A Howie 1, J R Wade 1, H L Elliott 1
PMCID: PMC1364639  PMID: 9114905

Abstract

1. Eighteen healthy, normotensive subjects (nine young and nine elderly) participated in a double-blind, 3-way, crossover study to compare aspects of the pharmacokinetics and pharmacodynamics of single oral doses of 10 mg benazepril, 10 mg enalapril and placebo. 2. The hypotensive effect was similar after both drugs but the absolute reductions were greater in the elderly who had higher initial levels of blood pressure. 3. The AUCs for both benazeprilat and enalaprilat were higher in the elderly but by a significantly greater amount for enalaprilat (+ 113% vs 40%; P < 0.01). 4. The AUCs for both drugs tended to be highest in subjects with the lowest creatinine clearance. 5. The changes in kinetics and dynamics observed in the elderly after benazepril are qualitatively similar to those with other ACE inhibitors. The clinical significance of the quantitative differences requires further investigation.

Full text

PDF
205

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chiknas S. G. A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum. Clin Chem. 1979 Jul;25(7):1259–1262. [PubMed] [Google Scholar]
  2. Cooper W. D., Sheldon D., Brown D., Kimber G. R., Isitt V. L., Currie W. J. Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice. J R Coll Gen Pract. 1987 Aug;37(301):346–349. [PMC free article] [PubMed] [Google Scholar]
  3. Hockings N., Ajayi A. A., Reid J. L. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol. 1986 Apr;21(4):341–348. doi: 10.1111/j.1365-2125.1986.tb05205.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hodsman G. P., Isles C. G., Murray G. D., Usherwood T. P., Webb D. J., Robertson J. I. Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed) 1983 Mar 12;286(6368):832–834. doi: 10.1136/bmj.286.6368.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jenkins A. C., Knill J. R., Dreslinski G. R. Captopril in the treatment of the elderly hypertensive patient. Arch Intern Med. 1985 Nov;145(11):2029–2031. [PubMed] [Google Scholar]
  6. Kaiser G., Ackermann R., Dieterle W., Durnin C. J., McEwen J., Ghose K., Richens A., Holmes I. B. Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. Eur J Clin Pharmacol. 1990;38(4):379–385. doi: 10.1007/BF00315579. [DOI] [PubMed] [Google Scholar]
  7. Kaiser G., Ackermann R., Sioufi A. Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. Am Heart J. 1989 Mar;117(3):746–751. doi: 10.1016/0002-8703(89)90765-5. [DOI] [PubMed] [Google Scholar]
  8. Lees K. R., Reid J. L. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clin Pharmacol Ther. 1987 Jun;41(6):597–602. doi: 10.1038/clpt.1987.81. [DOI] [PubMed] [Google Scholar]
  9. Lijnen P., Fagard R., Groeseneken D., M'Buyamba J. R., Staessen J., Amery A. The hypotensive effect of captopril in hypertensive patients is age-related. Methods Find Exp Clin Pharmacol. 1983 Nov;5(9):655–660. [PubMed] [Google Scholar]
  10. Man in 't Veld A. J., Schicht I. M., Derkx F. H., de Bruyn J. H., Schalekamp M. A. Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. Br Med J. 1980 Feb 2;280(6210):288–290. doi: 10.1136/bmj.280.6210.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Reid J. L., Macdonald N. J., Lees K. R., Elliott H. L. Angiotensin-converting enzyme inhibitors in the elderly. Am Heart J. 1989 Mar;117(3):751–755. doi: 10.1016/0002-8703(89)90766-7. [DOI] [PubMed] [Google Scholar]
  12. Sioufi A., Pommier F., Kaiser G., Dubois J. P. Determination of benazepril, a new angiotensin-converting enzyme inhibitor, and its active metabolite, benazeprilat, in plasma and urine by capillary gas chromatography-mass-selective detection. J Chromatogr. 1988 Dec 29;434(1):239–246. doi: 10.1016/0378-4347(88)80082-3. [DOI] [PubMed] [Google Scholar]
  13. Webster J., Newnham D. M., Petrie J. C. Initial dose of enalapril in hypertension. Br Med J (Clin Res Ed) 1985 Jun 1;290(6482):1623–1624. doi: 10.1136/bmj.290.6482.1623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Weidmann P., De Myttenaere-Bursztein S., Maxwell M. H., de Lima J. Effect on aging on plasma renin and aldosterone in normal man. Kidney Int. 1975 Nov;8(5):325–333. doi: 10.1038/ki.1975.120. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES